RJA
SYRS

Raymond James & Associates’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Raymond James & Associates’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,550
Closed -$84K – 4281
2021
Q2 		$84K Buy
+1,550
New +$91.7K ﹤0.01% 3865

Other funds holding SYRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Raymond James & Associates's SYRS Position: Q3 2021 in Review

Raymond James & Associates sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q3 2021, closing a stake of 1,550 shares — an estimated $84K sold.

Raymond James & Associates first reported a position in SYRS in Q2 2021 and held it in 1 quarter. The position peaked at $84K in Q2 2021. 100 funds tracked by Wall St. Rank hold SYRS as of Q3 2021.

  • Raymond James & Associates reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Raymond James & Associates sold 1,550 Syros Pharmaceuticals, Inc. Common Stock shares in Q3 2021, an estimated $84K.
  • Raymond James & Associates first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q2 2021 and held it in 1 quarter.
  • Raymond James & Associates's Syros Pharmaceuticals, Inc. Common Stock position peaked at $84K in Q2 2021.
  • 100 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q3 2021.

Based on Raymond James & Associates's 13F filing for Q3 2021, filed 2 Nov 2021.